Biblio

Export 1939 results:
Author Title [ Type(Desc)] Year
Filters: First Letter Of Last Name is B  [Clear All Filters]
Journal Article
R. Santangelo, Cecchetti, G., Bernasconi, M. Paola, Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comi, G., and Magnani, G., Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease., J Alzheimers Dis, vol. 60, no. 1, pp. 183-200, 2017.
R. Santangelo, Cecchetti, G., Bernasconi, M. Paola, Cardamone, R., Barbieri, A., Pinto, P., Passerini, G., Scomazzoni, F., Comi, G., and Magnani, G., Cerebrospinal Fluid Amyloid-β 42, Total Tau and Phosphorylated Tau are Low in Patients with Normal Pressure Hydrocephalus: Analogies and Differences with Alzheimer's Disease., J Alzheimers Dis, vol. 60, no. 1, pp. 183-200, 2017.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage., J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage., J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
B. M. Bettcher, Johnson, S. C., Fitch, R., Casaletto, K. B., Heffernan, K. S., Asthana, S., Zetterberg, H., Blennow, K., Carlsson, C. M., Neuhaus, J., Bendlin, B. B., and Kramer, J. H., Cerebrospinal Fluid and Plasma Levels of Inflammation Differentially Relate to CNS Markers of Alzheimer's Disease Pathology and Neuronal Damage., J Alzheimers Dis, vol. 62, no. 1, pp. 385-397, 2018.
M. Carmona-Iragui, Fernández-Arcos, A., Alcolea, D., Piazza, F., Morenas-Rodriguez, E., Antón-Aguirre, S., Sala, I., Clarimón, J., Dols-Icardo, O., Camacho, V., Sampedro, F., Munuera, J., Nuñez-Marin, F., Lleo, A., Fortea, J., Gómez-Ansón, B., and Blesa, R., Cerebrospinal Fluid Anti-Amyloid-β Autoantibodies and Amyloid PET in Cerebral Amyloid Angiopathy-Related Inflammation., J Alzheimers Dis, vol. 50, no. 1, pp. 1-7, 2016.
E. Niemantsverdriet, Ottoy, J., Somers, C., De Roeck, E., Struyfs, H., Soetewey, F., Verhaeghe, J., Van den Bossche, T., Van Mossevelde, S., Goeman, J., De Deyn, P. Paul, Mariën, P., Versijpt, J., Sleegers, K., Van Broeckhoven, C., Wyffels, L., Albert, A., Ceyssens, S., Stroobants, S., Staelens, S., Bjerke, M., and Engelborghs, S., The Cerebrospinal Fluid Aβ1-42/Aβ1-40 Ratio Improves Concordance with Amyloid-PET for Diagnosing Alzheimer's Disease in a Clinical Setting., J Alzheimers Dis, vol. 60, no. 2, pp. 561-576, 2017.
P. Lewczuk, Matzen, A., Blennow, K., Parnetti, L., Molinuevo, J. Luis, Eusebi, P., Kornhuber, J., Morris, J. C., and Fagan, A. M., Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease., J Alzheimers Dis, vol. 55, no. 2, pp. 813-822, 2017.
A. P. Ingber, Hassenstab, J., Fagan, A. M., Benzinger, T. L. S., Grant, E. A., Holtzman, D. M., Morris, J. C., and Roe, C. M., Cerebrospinal Fluid Biomarkers and Reserve Variables as Predictors of Future "Non-Cognitive" Outcomes of Alzheimer's Disease., J Alzheimers Dis, vol. 52, no. 3, pp. 1055-64, 2016.
C. B. Malpas, Saling, M. M., Velakoulis, D., Desmond, P., Hicks, R. J., Zetterberg, H., Blennow, K., and O'Brien, T. J., Cerebrospinal Fluid Biomarkers are Differentially Related to Structural and Functional Changes in Dementia of the Alzheimer's Type., J Alzheimers Dis, vol. 62, no. 1, pp. 417-427, 2018.
G. P. Paraskevas, Kasselimis, D., Kourtidou, E., Constantinides, V., Bougea, A., Potagas, C., Evdokimidis, I., and Kapaki, E., Cerebrospinal Fluid Biomarkers as a Diagnostic Tool of the Underlying Pathology of Primary Progressive Aphasia., J Alzheimers Dis, vol. 55, no. 4, pp. 1453-1461, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team., J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team., J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team., J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
S. P. Arnerić, Batrla-Utermann, R., Beckett, L., Bittner, T., Blennow, K., Carter, L., Dean, R., Engelborghs, S., Genius, J., Gordon, M. Forrest, Hitchcock, J., Kaplow, J., Luthman, J., Meibach, R., Raunig, D., Romero, K., Samtani, M. N., Savage, M., Shaw, L., Stephenson, D., Umek, R. M., Vanderstichele, H., Willis, B., and Yule, S., Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team., J Alzheimers Dis, vol. 55, no. 1, pp. 19-35, 2017.
M. Bjerke and Engelborghs, S., Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis., J Alzheimers Dis, vol. 62, no. 3, pp. 1199-1209, 2018.
S. Abu-Rumeileh, Mometto, N., Bartoletti-Stella, A., Polischi, B., Oppi, F., Poda, R., Stanzani-Maserati, M., Cortelli, P., Liguori, R., Capellari, S., and Parchi, P., Cerebrospinal Fluid Biomarkers in Patients with Frontotemporal Dementia Spectrum: A Single-Center Study., J Alzheimers Dis, vol. 66, no. 2, pp. 551-563, 2018.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years., J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years., J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
M. Bjerke, Kern, S., Blennow, K., Zetterberg, H., Waern, M., Börjesson-Hanson, A., Östling, S., Kern, J., and Skoog, I., Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years., J Alzheimers Dis, vol. 49, no. 3, pp. 733-41, 2016.
A. Arighi, Di Cristofori, A., Fenoglio, C., Borsa, S., D'Anca, M., Fumagalli, G. Giulio, Locatelli, M., Carrabba, G., Pietroboni, A. Margherita, Ghezzi, L., Carandini, T., Colombi, A., Scarioni, M., De Riz, M. Alessandra, Serpente, M., Rampini, P. Maria, Scarpini, E., and Galimberti, D., Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?, J Alzheimers Dis, vol. 69, no. 3, pp. 663-669, 2019.
N. P. Rocha, Toledo, A., Corgosinho, L. T. S., de Souza, L. C., Guimarães, H. C., Resende, E. P. F., Braz, N. F. T., Gomes, K. B., Silva, A. C. Simoes E., Caramelli, P., and Teixeira, A. L., Cerebrospinal Fluid Levels of Angiotensin-Converting Enzyme Are Associated with Amyloid-β42 Burden in Alzheimer's Disease., J Alzheimers Dis, vol. 64, no. 4, pp. 1085-1090, 2018.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia., Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia., Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease., J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.

Pages